Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1

Abstract

Background/Aim: This study aimed to evaluate the prognostic significance of PLA2G2A expression in patients with locally advanced gastric cancer (GC). Patients and Methods: PLA2G2A expression levels in cancerous tissue specimens and adjacent normal mucosa obtained from 134 patients with stage II/III GC who received adjuvant chemotherapy with S-1 after curative resection were measured using real-time quantitative polymerase chain reaction. Subsequently, the associations of PLA2G2A expression with clinicopathological features and survival were evaluated. Results: No association was observed between clinicopathological features and PLA2G2A expression levels. Overall survival was significantly longer in patients with high PLA2G2A expression levels (p=0.022). Multivariate analysis revealed that PLA2G2A expression was a significant, independent prognostic factor (hazard ratio=0.136; 95% confidence interval=0.0185-0.992; p=0.049). Conclusion: PLA2G2A mRNA expression may serve as a useful prognostic marker in patients with locally advanced GC who receive curative surgery and adjuvant chemotherapy with S-1. Patients and MethodsPatients and samples. Approval was received from the Ethics Committees of Yokohama City University and Yokohama City Medical Center (approval number: 18-7A-4) as well as Kanagawa Cancer Center (approval number: epidemiological study-29) before 3583

Stachydrine represses the proliferation and enhances cell cycle arrest and apoptosis of breast cancer cells via PLA2G2A/DCN axis

“…When seeking the possible candidate(s) in our study, PLA2G2A emerged and was regarded to interact with Stachydrine in BC. On the basis of the existing documents, we summarized that PLA2G2A is indeed associated with assorted types of malignancies like prostate cancer, gastric cancer, and most importantly, BC (Chen et al., 2017; Hatori et al., 2021; Jespersen et al., 2021; Ozturk et al., 2020). However, there is a paucity of knowledge concerning the specific effects of PLA2G2A in BC, apart from an existing study suggesting a subtype of PLA2G2A + cancer‐associated fibroblasts enriched in HER2 + BC patients that promotes immune infiltration (Liu et al., 2022).…”

“…Besides, targeting arachidonic acid (AA) pathway (a metabolic process playing key roles in carcinogenesis) and its metabolic enzymes including Phospholipase A 2 s (PLA 2 s) by natural products can be a possible way for cancer prevention and therapy (Yarla et al., 2016). As a member of the PLA 2 s enzymes that are small lipolytic hydrolases with the capability to modulate immune responses via generating AA, PLA2G2A is related to different types of malignancies, like prostate cancer, gastric cancer, and most importantly, BC (Chen et al., 2017; Hatori et al., 2021; Jespersen et al., 2021; Ozturk et al., 2020). A previous study showed that PLA2G2A is the most clinically relevant enzyme producing extracellular AA, and AA contributes to unfavorable clinical outcomes in ovarian cancer by affecting the phenotype of tumor‐associated macrophages (Dietze et al., 2021).…”

Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells

“…As the family member of phospholipase A2 (PLA2), PLA2G2A and PLA2G4A have a variety of biological functions, such as the involvement of cell signaling and in ammatory response [36,37]. PLA2G2A and PLA2G4A have also found to be involved in the pathogenesis of cancer, such as gastric cancer, colorectal cancer, prostrate cancer, and so on [38][39][40][41]. Some studies have found that the expression of PLA2G2A gene in the mice can be suppressed by thyroid hormone [42,43].…”